NasdaqGM:TMDXMedical Equipment
TransMedics Group (TMDX) Could Be 41% Undervalued As Earnings And Guidance Land
TransMedics Group (TMDX) is back in focus after reporting second quarter 2026 results on 4 August, pairing higher revenue with a lower net income figure and a small upward tweak to full year guidance.
See our latest analysis for TransMedics Group.
The earnings release and higher full year revenue guidance help explain why TransMedics Group’s recent momentum is strong, with a 30 day share price return of 19.09% and a 90 day share price return of 23.66%. This is despite the year to date share...